Reports progress of the Phase II long-term dosing trial and continued height growth effects in responding patients. AGV improvement was observed in patients with long-term dosing who responded, while non-responders showed no sustained effect. Monitor potential future dose adjustments. No impact on the fiscal year ending March 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4591","jir_company_name":"Ribomic Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4591-20261006-01.pdf","jir_short_summary":"Reports progress of the Phase II long-term dosing trial and continued height growth effects in responding patients. AGV improvement was observed in patients with long-term dosing who responded, while non-responders showed no sustained effect. Monitor potential future dose adjustments. No impact on the fiscal year ending March 2027.","jir_summary":"### Key Points\nThis report provides data on the progress of the Phase II long-term dosing trial of umedaptanib pegol and the continued efficacy observed in responding patients. It reports the trajectory of height growth velocity by dosing cohort and safety assessments. The responding cohort continued to show growth-promoting effects, whereas cohorts that did not achieve response showed no improvement in responsiveness. Future dose adjustment effects will be closely monitored.\n\n### Impact on Investors and Outlook\nWhile cases of sustained response with long-term dosing have been confirmed, insufficient efficacy in non-responding cohorts may affect future clinical development strategy (dose optimization and reassessment of target populations). It is explicitly stated that there is no impact on results for the fiscal year ending March 2027.","jir_financial_highlights":"AGV (Annualized Growth Velocity): Unknown (With long-term dosing, the responding group showed sustained growth-promoting effects; the non-responding group showed no improvement)\nImpact on financial results due to this matter: Unknown (There is no impact on results for the fiscal year ending March 2027)","jir_category":"","jir_hashtags":"#Ribomic, #ClinicalTrial, #LongTermDosing, #ACHTreatment","jir_key_figures":"AGV (Annualized Growth Velocity): Unknown\nImpact on results for the fiscal year ending March 2027 due to this matter: Unknown (not stated)\nComparison between responding and non-responding cohorts: Unknown (quantitative data not published)","jir_meta_title":"Ribomic Inc. Reports Progress of Long-Term Dosing Trial for Achondroplasia Treatment \uff5c October 2026","jir_meta_description":"Ribomic Inc. disclosed interim progress of the Phase II long-term dosing trial of umedaptanib pegol and continued efficacy in responding patients. Responding cohorts maintained growth-promoting effects; non-responding cohorts showed no improvement. No impact on fiscal year 2027 results.","jir_og_title":"Ribomic Inc. \u2014 Long-Term Dosing Trial Results and Outlook","jir_og_description":"In the long-term dosing trial of umedaptanib pegol, responding patients maintained growth-promoting effects. Non-responding cohorts showed no improvement. No impact on the fiscal year ending March 2027.","jir_og_image_url":"\/assets\/og\/company-product_announcement.jpg","jir_chart_data_collection":"[]","ir_related_company":60243,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-127812","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n